Research Dive’s Post

Failure is not an option! 90% of drug candidates fail in clinical trials. This represents a significant economic burden for the industry. 📉🏭 Adopting novel, efficient, and scalable technologies in high-throughput screening is pivotal in this regard.🔬💡So let’s turbocharge your qPCR screening to ultra-high throughput. 👉 Learn more in our new article: https://lnkd.in/eNPt58y6 #GreinerBioOne #makingadifference #Drugdiscovery #HTS #HighThroughputScreening

Enjoyed these publications on decentralised manufacturing authored by Domhnall Mc Gowan at Canadian Advanced Therapies Training Institute and Erika Francoeur at Boston Labs. Across four papers the authors discuss a variety of topics: 🔆 1️⃣ the evolution of decentralised manufacturing from centralised manufacturing and its importance in ubiquitous access of these therapeutics https://lnkd.in/e-hFUN9D 🌟 2️⃣ the utilisation of emerging technologies within #cellandgenetherapies such automated closed systems, highlighted especially by the Miltenyi Biotec Prodigy and Lonza's Cocoon. Equipment for tracking and transport logistics for chain of custody and chain of identification with systems such Vineti feature too. Not mentioned but Hataali is another interesting system as well. A quick overview of quality management, QC & Product testing also ensues. https://lnkd.in/ekm4iRC7 😎 3️⃣ This post couldn't be published without a discussion on #skills as well. In the third publication the authors interview three individuals across some of the challenges in developing a competent and sustainable workforce within the sector. https://lnkd.in/eYZVAGmU 📊 4️⃣ Last but not least in the fourth installment an overview of CAR-T bioprocessing is provided with considerations on how decentralised manufacturing could provide new paradigms in therapeutics accessibility. https://lnkd.in/ekSQ2GAE Craig Hasilo, Benjamin McLeod, Spencer Knight, Ry Leahy #skills, #communitybuilding, #bioprocessing, #manufacturing,

🚀 Global Momentum for Organ-on-Chip Technology 🚀 At Beonchip, we are thrilled to witness the growing global recognition of organ-on-chip (OoC) technology as a revolutionary tool in drug discovery and biomedical research. 🌍 Recently, India launched its BioE3 policy, a forward-thinking initiative that promotes the use of OoC systems in biotechnology innovation. This strategic move aligns with global trends, particularly after the U.S. FDA Modernization Act 2.0, which formally recognized OoC models as a cutting-edge alternative to traditional animal testing. These developments underscore a shared commitment to enhancing precision in drug development, reducing animal reliance, and accelerating innovation across borders. As a company committed to advancing organ-on-chip design, production, and commercialization, we’re excited to be part of this global movement shaping the future of biotech! If you want to know more about this topic, check out the article "How Industry Embraces Organ-on-Chips: A 2024 Status Report" in the following link 🔗 https://lnkd.in/dE3Cf9v5 #OrganOnChip #DrugDiscovery #Innovation #Beonchip #Biotech #FDA #BioE3 #PrecisionMedicine

I enjoyed sharing some background on ways that companies are looking to speed up cell line development in the bioprocessing industry using novel selection strategies, transposons and site-directed integration in this short article in Bioprocess Online https://lnkd.in/g87qw4Ue

🔍 Get ready for an enlightening exploration of Allogeneic roundtable discussion at the Cell Therapy Manufacturing Xchange in Boston 2024! 🔍 📌 Reserve your spot and get your Complimentary Pass now: https://bit.ly/3VLMt2O Don't let this exclusive opportunity pass you by. Immerse yourself in dynamic discussions, interactive sessions, and unmatched networking opportunities with industry peers. 💫 Here's a sneak peek of what's awaiting you: 🖊️ Determining the allogenic platform to generate a safe and efficacious therapy 👤Suchit Sahai, Associate Director, Kite Pharma 🖊 Manufacturing and scale-up challenges in allogeneic cell therapy development 👤 Shankar Swaminathan, Ph.D., Associate Director Drug Product Development, Astellas Pharma Institute for Regenerative Medicine 💊 This event is exclusively tailored for Senior Scientists and above, representing esteemed Bio and Pharma companies with a robust drug pipeline. 💊 🤝 Our Partners ⚪ Monomer Bio ⚪ Akron Bio ⚪ WuXi Advanced Therapies ⚪ Terumo Blood and Cell Technologies ⚪ Miltenyi Biotec ⚪ Mission Bio *Agenda subject to change #CellTherapyManufacturing #iPSCs #AllogeneicCellTherapy #Biotechnology #STEM #BiotechEvent #PharmaInnovation #BostonEvents #RegenerativeMedicine #CellularTherapies #InnovativeMedicine #TherapeuticAdvancements #LifeSciencesEvent #InnovationInHealthcare #BiotechCommunity #MedicalInnovation #ScienceAndTechnology #HealthTech #NetworkingEvent #BostonBiotech #RegenMed #PrecisionMedicine #HealthcareInnovation #Roundtable #Xchange #hubXchange #RegisterNow #ComplimentaryPass

9 Innovative Life Sciences Companies to Watch in 2024 Read the latest article by Bohdana Sokolova, author at BiopharmaTrend 👇 #biopharmatrend #biotech #drugdiscovery #technology https://lnkd.in/dsCHnMdy

Checkout the NutriFreez® D10 Cryopreservation Medium by Sartorius — available now at FroggaBio! A serum-free, protein-free solution for optimal cell viability and bioactivity post-cryopreservation. 🐸 🔬❄️ LEARN MORE: https://hubs.li/Q02mpb-R0 Experience superior cell preservation with NutriFreez® D10 Cryopreservation Medium, ensuring high rates of viability and adherence across various cell types. Ideal for sensitive cells and stem cells, this solution is cGMP manufactured and ready-to-use. #CellPreservation #StemCells #Biopharma #Research #Cryopreservation #Science #LabLife #Innovation #FroggaBio Sartorius Stedim Biotech Biological Industries/Sartorius Israel Sartorius CellGenix GmbH Sartorius Food & Beverage Sartorius Korea Biotech Sartorius Sartonet Türkiye #BioTech #Healthcare #STEM #CellCulture #RegenerativeMedicine #Bioengineering #AnimalComponentFree #ProteinFree #SerumFree #HighViability #CellViability #LabSupplies #ScientificResearch #PharmaTech #LifeSciences #LabResearch #Discoveries

🚀 Vaccine Manufacturing Made Simpler! 🚀 Exciting to share a landmark study: "Seed Train Optimization in Microcarrier-Based Cell Culture Post In Situ Cell Detachment through Scale-Down Hybrid Modeling." This research introduces a groundbreaking approach to culturing cells for vaccine production, making the process more efficient and scalable. 🧬✨ Key findings: -Serial subculturing on microcarriers with in situ cell detachment. Optimized growth conditions leading to higher cell densities. -A game-changer for vaccine production, promising to speed up and scale the manufacturing process like never before! 🌍💉 Let's discuss how these findings could transform the biotech industry and improve global health outcomes. What are your thoughts on the scalability and efficiency of current vaccine production methods? Read More: https://lnkd.in/g_wHcDzS #Innovation #VaccineDevelopment #Biotech #ScienceImpact #HealthTech

𝐀 𝐃𝐞𝐞𝐩 𝐃𝐢𝐯𝐞 𝐢𝐧𝐭𝐨 𝐭𝐡𝐞 𝐂𝐞𝐥𝐥 𝐈𝐬𝐨𝐥𝐚𝐭𝐢𝐨𝐧/𝐒𝐞𝐩𝐚𝐫𝐚𝐭𝐢𝐨𝐧 𝐌𝐚𝐫𝐤𝐞𝐭: 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 𝐚𝐧𝐝 𝐂𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬 𝑫𝒐𝒘𝒏𝒍𝒐𝒂𝒅 𝑷𝑫𝑭 𝑩𝒓𝒐𝒄𝒉𝒖𝒓𝒆>> bit.ly/4bUJlWA The cell isolation market is projected to reach USD 8.4 billion by 2029 from an estimated USD 4.6 billion in 2024, at a CAGR of 12.9% during the forecast period of 2024 to 2029. 𝐌𝐚𝐫𝐤𝐞𝐭 𝐃𝐲𝐧𝐚𝐦𝐢𝐜𝐬:   Drivers ·        Increasing government funding for cell-based research ·        Surge in cases of cancer and infectious diseases ·        Rising emphasis on technological advancements and product developments ·        Growing focus on personalized medicine  Restraints ·        Ethical and safety issues ·        High cost of cell-based research  Opportunities ·        Growth opportunities in emerging economies ·        Increasing focus on next-generation therapeutics  Challenges ·        Complex development process of cell therapies ·        Technical complexities and stringent regulatory requirements 𝐊𝐞𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 Merck KGaA, Darmstadt, Germany Danaher Corporation Thermo Fisher Scientific BD Agilent Technologies Miltenyi Biotec Revvity Sartorius Roche Lonza QIAGEN Alfa Laval Terumo Medical Corporation Corning Incorporated Bio-Rad Laboratories GenScript Bio-Techne Takara Bio Inc. Standard BioTools Promega Corporation Cell Signaling Technology (CST) STEMCELL Technologies #CellIsolation #CellSeparation #Biotechnology #CellTherapy #LifeSciences #BiomedicalResearch #StemCells #LaboratoryScience #MedicalResearch #CellSorting #FlowCytometry #Microfluidics #CellBiology #Genomics #Proteomics #HealthcareInnovation #LabTech #ResearchAndDevelopment #BiotechIndustry #CellCulture 

Honored that Bohdana Sokolova in BiopharmaTrend.com named us as a top innovator to watch in 2024. Sokolova’s article notes the wave of innovation and technological advancement sweeping through the biotech and pharmaceutical industries. She explores our pioneering #proteindesign efforts, including our groundbreaking work in “generating new proteins de novo” and our “optimization suite that refines native proteins into effective therapeutics for specific targets.” Read Sokolova’s full article below 👇🏻 #GenerativeAI | #ProteinEngineering